Floatz logo

(+)-VINCRISTINE

Malignant Female Reproductive System Neoplasm

AbbVieSmall moleculePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Malignant Female Reproductive System Neoplasm cohort.

Asset / SponsorPhaseRating
Irinotecan
AbbVie
Phase 2BB
Ipilimumab
M.D. Anderson Cancer Center
Phase 2B
Eloxatin
National Cancer Institute (NCI)
Phase 2B
azd6244
National Cancer Institute (NCI)
Phase 2B
AZD1775
National Cancer Institute (NCI)
Phase 2B

View all 24 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →